Nanoroughened adhesion-based capture of circulating tumor cells with heterogeneous expression and metastatic characteristics

Weiqiang Chen, Steven G. Allen, Ajaya Kumar Reka, Weiyi Qian, Shuo Han, Jianing Zhao, Liwei Bao, Venkateshwar G. Keshamouni, Sofia D. Merajver, Jianping Fu

Research output: Contribution to journalArticle

Abstract

Background: Circulating tumor cells (CTCs) have shown prognostic relevance in many cancer types. However, the majority of current CTC capture methods rely on positive selection techniques that require a priori knowledge about the surface protein expression of disseminated CTCs, which are known to be a dynamic population. Methods: We developed a microfluidic CTC capture chip that incorporated a nanoroughened glass substrate for capturing CTCs from blood samples. Our CTC capture chip utilized the differential adhesion preference of cancer cells to nanoroughened etched glass surfaces as compared to normal blood cells and thus did not depend on the physical size or surface protein expression of CTCs. Results: The microfluidic CTC capture chip was able to achieve a superior capture yield for both epithelial cell adhesion molecule positive (EpCAM+) and EpCAM- cancer cells in blood samples. Additionally, the microfluidic CTC chip captured CTCs undergoing transforming growth factor beta-induced epithelial-to-mesenchymal transition (TGF-β-induced EMT) with dynamically down-regulated EpCAM expression. In a mouse model of human breast cancer using EpCAM positive and negative cell lines, the number of CTCs captured correlated positively with the size of the primary tumor and was independent of their EpCAM expression. Furthermore, in a syngeneic mouse model of lung cancer using cell lines with differential metastasis capability, CTCs were captured from all mice with detectable primary tumors independent of the cell lines' metastatic ability. Conclusions: The microfluidic CTC capture chip using a novel nanoroughened glass substrate is broadly applicable to capturing heterogeneous CTC populations of clinical interest independent of their surface marker expression and metastatic propensity. We were able to capture CTCs from a non-metastatic lung cancer model, demonstrating the potential of the chip to collect the entirety of CTC populations including subgroups of distinct biological and phenotypical properties. Further exploration of the biological potential of metastatic and presumably non-metastatic CTCs captured using the microfluidic chip will yield insights into their relevant differences and their effects on tumor progression and cancer outcomes.

Original languageEnglish (US)
Article number614
JournalBMC Cancer
Volume16
Issue number1
DOIs
StatePublished - Aug 8 2016

Fingerprint

Circulating Neoplastic Cells
Microfluidics
Glass
Neoplasms
Lung Neoplasms
Blood Cells
Membrane Proteins
Cell Line
Epithelial-Mesenchymal Transition

Keywords

  • Adhesion
  • Breast cancer
  • Circulating tumor cells
  • Lung cancer
  • Metastasis
  • Microfluidics

ASJC Scopus subject areas

  • Genetics
  • Oncology
  • Cancer Research

Cite this

Nanoroughened adhesion-based capture of circulating tumor cells with heterogeneous expression and metastatic characteristics. / Chen, Weiqiang; Allen, Steven G.; Reka, Ajaya Kumar; Qian, Weiyi; Han, Shuo; Zhao, Jianing; Bao, Liwei; Keshamouni, Venkateshwar G.; Merajver, Sofia D.; Fu, Jianping.

In: BMC Cancer, Vol. 16, No. 1, 614, 08.08.2016.

Research output: Contribution to journalArticle

Chen, W, Allen, SG, Reka, AK, Qian, W, Han, S, Zhao, J, Bao, L, Keshamouni, VG, Merajver, SD & Fu, J 2016, 'Nanoroughened adhesion-based capture of circulating tumor cells with heterogeneous expression and metastatic characteristics', BMC Cancer, vol. 16, no. 1, 614. https://doi.org/10.1186/s12885-016-2638-x
Chen, Weiqiang ; Allen, Steven G. ; Reka, Ajaya Kumar ; Qian, Weiyi ; Han, Shuo ; Zhao, Jianing ; Bao, Liwei ; Keshamouni, Venkateshwar G. ; Merajver, Sofia D. ; Fu, Jianping. / Nanoroughened adhesion-based capture of circulating tumor cells with heterogeneous expression and metastatic characteristics. In: BMC Cancer. 2016 ; Vol. 16, No. 1.
@article{70803031af3d4006be548c1e6e5bb37b,
title = "Nanoroughened adhesion-based capture of circulating tumor cells with heterogeneous expression and metastatic characteristics",
abstract = "Background: Circulating tumor cells (CTCs) have shown prognostic relevance in many cancer types. However, the majority of current CTC capture methods rely on positive selection techniques that require a priori knowledge about the surface protein expression of disseminated CTCs, which are known to be a dynamic population. Methods: We developed a microfluidic CTC capture chip that incorporated a nanoroughened glass substrate for capturing CTCs from blood samples. Our CTC capture chip utilized the differential adhesion preference of cancer cells to nanoroughened etched glass surfaces as compared to normal blood cells and thus did not depend on the physical size or surface protein expression of CTCs. Results: The microfluidic CTC capture chip was able to achieve a superior capture yield for both epithelial cell adhesion molecule positive (EpCAM+) and EpCAM- cancer cells in blood samples. Additionally, the microfluidic CTC chip captured CTCs undergoing transforming growth factor beta-induced epithelial-to-mesenchymal transition (TGF-β-induced EMT) with dynamically down-regulated EpCAM expression. In a mouse model of human breast cancer using EpCAM positive and negative cell lines, the number of CTCs captured correlated positively with the size of the primary tumor and was independent of their EpCAM expression. Furthermore, in a syngeneic mouse model of lung cancer using cell lines with differential metastasis capability, CTCs were captured from all mice with detectable primary tumors independent of the cell lines' metastatic ability. Conclusions: The microfluidic CTC capture chip using a novel nanoroughened glass substrate is broadly applicable to capturing heterogeneous CTC populations of clinical interest independent of their surface marker expression and metastatic propensity. We were able to capture CTCs from a non-metastatic lung cancer model, demonstrating the potential of the chip to collect the entirety of CTC populations including subgroups of distinct biological and phenotypical properties. Further exploration of the biological potential of metastatic and presumably non-metastatic CTCs captured using the microfluidic chip will yield insights into their relevant differences and their effects on tumor progression and cancer outcomes.",
keywords = "Adhesion, Breast cancer, Circulating tumor cells, Lung cancer, Metastasis, Microfluidics",
author = "Weiqiang Chen and Allen, {Steven G.} and Reka, {Ajaya Kumar} and Weiyi Qian and Shuo Han and Jianing Zhao and Liwei Bao and Keshamouni, {Venkateshwar G.} and Merajver, {Sofia D.} and Jianping Fu",
year = "2016",
month = "8",
day = "8",
doi = "10.1186/s12885-016-2638-x",
language = "English (US)",
volume = "16",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Nanoroughened adhesion-based capture of circulating tumor cells with heterogeneous expression and metastatic characteristics

AU - Chen, Weiqiang

AU - Allen, Steven G.

AU - Reka, Ajaya Kumar

AU - Qian, Weiyi

AU - Han, Shuo

AU - Zhao, Jianing

AU - Bao, Liwei

AU - Keshamouni, Venkateshwar G.

AU - Merajver, Sofia D.

AU - Fu, Jianping

PY - 2016/8/8

Y1 - 2016/8/8

N2 - Background: Circulating tumor cells (CTCs) have shown prognostic relevance in many cancer types. However, the majority of current CTC capture methods rely on positive selection techniques that require a priori knowledge about the surface protein expression of disseminated CTCs, which are known to be a dynamic population. Methods: We developed a microfluidic CTC capture chip that incorporated a nanoroughened glass substrate for capturing CTCs from blood samples. Our CTC capture chip utilized the differential adhesion preference of cancer cells to nanoroughened etched glass surfaces as compared to normal blood cells and thus did not depend on the physical size or surface protein expression of CTCs. Results: The microfluidic CTC capture chip was able to achieve a superior capture yield for both epithelial cell adhesion molecule positive (EpCAM+) and EpCAM- cancer cells in blood samples. Additionally, the microfluidic CTC chip captured CTCs undergoing transforming growth factor beta-induced epithelial-to-mesenchymal transition (TGF-β-induced EMT) with dynamically down-regulated EpCAM expression. In a mouse model of human breast cancer using EpCAM positive and negative cell lines, the number of CTCs captured correlated positively with the size of the primary tumor and was independent of their EpCAM expression. Furthermore, in a syngeneic mouse model of lung cancer using cell lines with differential metastasis capability, CTCs were captured from all mice with detectable primary tumors independent of the cell lines' metastatic ability. Conclusions: The microfluidic CTC capture chip using a novel nanoroughened glass substrate is broadly applicable to capturing heterogeneous CTC populations of clinical interest independent of their surface marker expression and metastatic propensity. We were able to capture CTCs from a non-metastatic lung cancer model, demonstrating the potential of the chip to collect the entirety of CTC populations including subgroups of distinct biological and phenotypical properties. Further exploration of the biological potential of metastatic and presumably non-metastatic CTCs captured using the microfluidic chip will yield insights into their relevant differences and their effects on tumor progression and cancer outcomes.

AB - Background: Circulating tumor cells (CTCs) have shown prognostic relevance in many cancer types. However, the majority of current CTC capture methods rely on positive selection techniques that require a priori knowledge about the surface protein expression of disseminated CTCs, which are known to be a dynamic population. Methods: We developed a microfluidic CTC capture chip that incorporated a nanoroughened glass substrate for capturing CTCs from blood samples. Our CTC capture chip utilized the differential adhesion preference of cancer cells to nanoroughened etched glass surfaces as compared to normal blood cells and thus did not depend on the physical size or surface protein expression of CTCs. Results: The microfluidic CTC capture chip was able to achieve a superior capture yield for both epithelial cell adhesion molecule positive (EpCAM+) and EpCAM- cancer cells in blood samples. Additionally, the microfluidic CTC chip captured CTCs undergoing transforming growth factor beta-induced epithelial-to-mesenchymal transition (TGF-β-induced EMT) with dynamically down-regulated EpCAM expression. In a mouse model of human breast cancer using EpCAM positive and negative cell lines, the number of CTCs captured correlated positively with the size of the primary tumor and was independent of their EpCAM expression. Furthermore, in a syngeneic mouse model of lung cancer using cell lines with differential metastasis capability, CTCs were captured from all mice with detectable primary tumors independent of the cell lines' metastatic ability. Conclusions: The microfluidic CTC capture chip using a novel nanoroughened glass substrate is broadly applicable to capturing heterogeneous CTC populations of clinical interest independent of their surface marker expression and metastatic propensity. We were able to capture CTCs from a non-metastatic lung cancer model, demonstrating the potential of the chip to collect the entirety of CTC populations including subgroups of distinct biological and phenotypical properties. Further exploration of the biological potential of metastatic and presumably non-metastatic CTCs captured using the microfluidic chip will yield insights into their relevant differences and their effects on tumor progression and cancer outcomes.

KW - Adhesion

KW - Breast cancer

KW - Circulating tumor cells

KW - Lung cancer

KW - Metastasis

KW - Microfluidics

UR - http://www.scopus.com/inward/record.url?scp=84981187578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981187578&partnerID=8YFLogxK

U2 - 10.1186/s12885-016-2638-x

DO - 10.1186/s12885-016-2638-x

M3 - Article

C2 - 27501846

AN - SCOPUS:84981187578

VL - 16

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 614

ER -